AXSM Stock After Record Climb: Why All Eyes are on Axsome Therapeutics
In a market stuffed with hundreds of micro-cap companies, AXSM stock could be called a break-out success. Because in only four months, Axsome Therapeutics (NASDAQ:AXSM) went from being a $3 penny stock to a lot ... [Read]
TGTX Stock Doubles in 2019 on Positive Umbralisib Results
TGTX stock has been crushing the market this year with its shares surging high following the news that TG Therapeutics’ (NASDAQ:TGTX) refractory and relapsed MZL drug candidate umbralisib has been granted orphan drug designation by ... [Read]
NVAX Stock: Novavax Gets Delisting Warning on Lower Price
Novavax Inc. (NASDAQ:NVAX) has been warned by Nasdaq that NVAX stock will be delisted should the price of the stock fail to get past a buck in the next six months. For 30 consecutive days, ... [Read]
Penny Stocks: Why You Should Watch AKTX and KODK in April
The penny stocks market is volatile, and investors can love it or hate it for this reason. Volatility means sudden and unexpected (and often unexplained) gains in the double and sometimes triple digits. If this ... [Read]
Penny Stocks to Watch: Will ADIL Shares Follow in AXSM’s Footsteps?
On the rise today is Adial Pharmaceuticals (NASDAQ:ADIL), up 2.27% and selling for $3.02 USD on the NASDAQ exchange. Penny stocks in the pharmaceutical industry are often an investor favorite. There are many reasons as ... [Read]
PHAS Stock Zooms 440%: What Next for PhaseBio Pharmaceuticals?
PHAS stock has been on fire over the past month, gaining over 440% during this period. Today PhaseBio Pharmaceuticals (NASDAQ:PHAS) is valued at more than $350 million. This week, PHAS stock leaped 32.5% after the ... [Read]
Penny Stocks to Watch: Investors are Talking About Axsome Therapeutics
When penny stocks triple their value, it makes you sit up and take notice. This is exactly what Axsome Therapeutics (NASDAQ:AXSM) has done for those lucky few who invested when Axsome was still a penny stock. ... [Read]
DERM Stock Doubles in a Month on Lebrikizumab’s Buzz
DERM stock investors are getting excited and for good reason too. Dermira (NASDAQ:DERM) released positive progress for a key drug candidate, lebrikizumab, back in mid-March and shares have been climbing since. Since March 15th, DERM stock ... [Read]
ZYNE Stock Zooms Over 50% This Week, What Next for Zynerba?
ZYNE stock continued to gain momentum in Friday’s session and was recently moving up by 10.36% to $8.53 USD, extending its winning streak for the fourth straight session. Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) are up ... [Read]
ACHN Stock Climbs After Achillion Pharmaceuticals’ Trial Fills Up
ACHN stock is one of the top performing biotech stocks so far in 2019. Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) are up over 115% since early January amid several key clinical updates. In Wednesday’s session, Achillion ... [Read]